News Release

Assessing outcomes of flexible boosting of CoronaVac COVID-19 vaccine

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: In this study using national data of nearly 14 million vaccinated individuals in Malaysia, researchers assessed the risk of symptomatic SARS-CoV-2 infection associated with two doses of the CoronaVac (Sinovac Biotech) COVID-19 vaccine plus a third dose or a Pfizer-BioNTech booster compared with two or three doses of the Pfizer-BioNTech vaccine.

Authors: Ee Vien Low, Ph.D., of the Ministry of Health Malaysia in Shah Alam, Malaysia, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.